Comparison of Phaco Surgery With Goniosynechialysis Versus Trabeculectomy in Glaucoma Treatment (NCT06952153) | Clinical Trial Compass
RecruitingNot Applicable
Comparison of Phaco Surgery With Goniosynechialysis Versus Trabeculectomy in Glaucoma Treatment
Vietnam82 participantsStarted 2025-06-01
Plain-language summary
The goal of this clinical trial is to learn whether phacoemulsification combined with goniosynechialysis (Phaco-GSL) is as effective and safe as trabeculectomy in treating patients with primary angle-closure glaucoma.
The main questions it aims to answer are:
* Does Phaco-GSL provide similar or better intraocular pressure (IOP) control compared to trabeculectomy?
* What are the rates of postoperative complications or adverse events between the two surgical approaches?
* How do the two procedures compare in terms of visual acuity recovery and need for glaucoma medications?
Researchers will compare Phaco-GSL to trabeculectomy to determine which procedure offers better overall outcomes for patients with angle-closure glaucoma.
Participants will:
Be randomly assigned to undergo either Phaco-GSL or trabeculectomy Attend scheduled follow-up visits at regular intervals (e.g., 1 week, 1 month, 3 months, 6 months, 12 months) for eye exams and pressure checks
Who can participate
Age range
40 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥ 40 years
* Peripheral anterior synechiae (PAS) \>180°
* Glaucomatous optic neuropathy with visual field loss
* Intraocular pressure (IOP) \> 21 mmHg despite medication
* Ability to consent and comply with follow-up
* Cataract grade 1 to 3 according to LOCS III
* Best corrected visual acuity (BCVA) ≥ 0.3 logMAR (equivalent to 20/40 Snellen or worse)
Exclusion Criteria:
* Very advanced glaucoma (only light perception vision)
* Secondary angle-closure etiologies
* Prior ocular surgeries or laser peripheral iridotomy (PI)
* Allergy to 5-fluorouracil (5-FU), if used postoperatively
* Irreversible corneal disease
* Chronic corticosteroid use
* Poor follow-up compliance
* Cataract grade 4 or 5 (LOCS III)
* Phacomorphic, phacolytic, or subluxated cataracts
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Mean change in intraocular pressure (IOP) from baseline
Timeframe: 12 months after surgery
Trial details
NCT IDNCT06952153
SponsorUniversity of Medicine and Pharmacy at Ho Chi Minh City